Revvity Q3 revenue $710M, 7% organic growth and raised full-year outlook
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Total Revenue: $710 million in Q3 2026, with 7% pro forma organic growth; FX ~1% headwind, ACD Labs acquisition ~1% contribution. Pro Forma Adjusted Operating Margin: 29.4% in Q3, ~40 basis points ahead of expectations; full-year outlook…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishOrganic growth and earnings above estimates with a raised outlook support the stock in life sciences.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 revenue was $710 million, with 7% pro forma organic growth.
- 02Pro forma adjusted EPS was $1.37, $0.08 above the midpoint of guidance.
- 03Pro forma adjusted operating margin was 29.4%.
- 04Free cash flow in the quarter was $152 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets